The firm's treatments are based on stimulating the innate immune system with drugs made from inactivated bacteria to restore normal immune function.
The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents.
The company said that changes it made in the fourth quarter, including a recently announced restructuring plan, will lead to improvements in 2017.
The firm said the assay provides flexible automation and accurately identifies all six HCV genotypes as well as subtypes 1a and 1b.
The firm said that the technologies it has licensed improve PCR and RT-PCR amplification of DNA and RNA.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.